Transporter-mediated uptake into cellular compartments

Xenobiotica

Volumn 37, Issue 10-11, 2007, Pages 1171-1195

  Oswald, S ^a   Grube, M ^a   Siegmund, W ^a   Kroemer, H K ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Blood cell transporters; Brain transporters; Cellular compartments; Clinical significance of transporters; Enterocyte transporters; Heart transporters; Hepatocyte transporters; Tissue transporters; Transporters; Uptake

Indexed keywords

ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; ATORVASTATIN; ATRASENTAN; CARBAMAZEPINE; CARDIAC AGENT; CARRIER PROTEIN; CENTRAL NERVOUS SYSTEM AGENTS; CERIVASTATIN; CYCLOSPORIN; DEXAMETHASONE; DIGOXIN; EZETIMIBE; FENOFIBRATE; FEXOFENADINE; GEMFIBROZIL; GLIBENCLAMIDE; IMMUNOSUPPRESSIVE AGENT; IRINOTECAN; NATEGLINIDE; PITAVASTATIN; PRAVASTATIN; PROTEINASE INHIBITOR; REPAGLINIDE; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSUVASTATIN; UNINDEXED DRUG; VALSARTAN;

BLOOD CELL; BRAIN CELL; DRUG BIOAVAILABILITY; DRUG METABOLISM; GRAPEFRUIT JUICE; HEART MUSCLE CELL; HUMAN; INTESTINE CELL; INTRACELLULAR SPACE; LIVER; LIVER CELL; NONHUMAN; PROTEIN TRANSPORT; REVIEW; SINGLE DRUG DOSE;

BIOLOGICAL TRANSPORT, ACTIVE; BLOOD CELLS; BRAIN; CARRIER PROTEINS; CELL COMPARTMENTATION; HEPATOCYTES; HUMANS; MODELS, BIOLOGICAL; MYOCARDIUM; P-GLYCOPROTEIN; XENOBIOTICS;

EID: 35648940290     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701570251     Document Type: Review

References (197)

1. Abraham EH, Shrivastav B, Salikhova AY, Sterling KM, Johnston N, Guidotti G, Scala S, Litman T, Chan KC, Arceci RJ, et al. 2001. Cellular and biophysical evidence for interactions between adenosine triphosphate and P-glycoprotein substrates: functional implications for adenosine triphosphate/drug cotransport in P-glycoprotein overexpressing tumor cells and in P-glycoprotein low-level expressing erythrocytes. Blood Cells, Molecular and Disease 27:181-200.
2. Aggarwal S, Tsuruo T, Gupta S. 1997. Altered expression and function of P-glycoprotein (170 kDa), encoded by the MDR 1 gene, in T cell subsets from aging humans. Journal of Clinical Immunology 17:448-454.
3. Altmann SW, Davis Jr, HR, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, et al. 2004. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303:1201-1204.
4. Anderle P, Huang Y, Sadee W. 2004. Intestinal membrane transport of drugs and nutrients: genomics of membrane transporters using expression microarrays. European Journal of Pharmaceutical Sciences 21:17-24.
5. Aronica E, Gorter JA, Ramkema M, Redeker S, Ozbas-Gerceker F, Van Vliet EA, Scheffer GL, Scheper RJ, van der Valk P, Baayen JC, et al. 2004. Expression and cellular distribution of multidrug resistance-related proteins in the hippocampus of patients with mesial temporal lobe epilepsy. Epilepsia 45:441-451.
6. Ayrton A, Morgan P. 2001. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31:469-497.
7. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. 2002. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clinical Pharmacology and Therapeutics 72:685-691.
8. Backman JT, Luurila H, Neuvonen M, Neuvonen PJ. 2005. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites. Clinical Pharmacology and Therapeutics 78:154-167.
9. Barr WH, Zola EM, Candler EL, Hwang SM, Tendolkar AV, Shamburek R, Parker B, Hilty MD. 1994. Differential absorption of amoxicillin from the human small and large intestine. Clinical Pharmacology and Therapeutics 56:279-285.
10. Bauer B, Hartz AM, Fricker G, Miller DS. 2005. Modulation of p-glycoprotein transport function at the blood-brain barrier. Experimental Biology and Medicine (Maywood) 230:118-127.
11. Boulton DW, DeVane CL, Liston HL, Markowitz JS. 2002. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Science 71:163-169.
12. Cascorbi I. 2006. Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacology and Therapy 112:457-473.
13. Ceckova-Novotna M, Pavek P, Staud F. 2006. P-glycoprotein in the placenta: Expression, localization, regulation and function. Reproductive Toxicology 22:400-410.
14. Chan KK, Buch A, Glazer RD, John VA, Barr WH. 1994. Site-differential gastrointestinal absorption of benazepril hydrochloride in healthy volunteers. Pharmaceutical Research 11:432-437.
15. Chan LM, Lowes S, Hirst BH. 2004. The ABCs of drug transport in intestine and liver: Efflux proteins limiting drug absorption and bioavailability. European Journal of Pharmaceutical Sciences 21:25-51.
16. Chandra P, Brouwer KL. 2004. The complexities of hepatic drug transport: Current knowledge and emerging concepts. Pharmaceutical Research 21:719-735.
17. Chaudhary PM, Mechetner EB, Roninson IB. 1992. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 80:2735-2739.
18. Chen ZS, Lee K, Kruh GD. 2001. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. Journal of Biological Chemistry 276:33747-33754.
19. Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, Lim KS, Moon KH, Shin SG, Jang IJ. 2005. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clinical Pharmacology and Pharmaceutical Reviews 78:342-350.
20. Couture L, Nash JA, Turgeon J. 2006. The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart. Pharmaceutical Reviews 58:244-258.
21. Coves-Orts FJ, Borras-Blasco J, Navarro-Ruiz A, Murcia-Lopez A, Palacios-Ortega F. 2005. Acute seizures due to a probable interaction between valproic acid and meropenem. Annals of Pharmacotherapy 39:533-537.
22. Dallas S, Miller DS, Bendayan R. 2006. Multidrug resistance-associated proteins: Expression and function in the central nervous system. Pharmaceutical Reviews 58:140-161.
23. Davies JP, Scott C, Oishi K, Liapis A, Ioannou YA. 2005. Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia. Journal of Biological Chemistry 280:12710-12720.
24. Dazert P, Meissner K, Vogelgesang S, Heydrich B, Eckel L, Bohm M, Warzok R, Kerb R, Brinkmann U, Schaeffeler E, et al. 2003. Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart. American Journal of Pathology 163:1567-1577.
25. DeSesso JM, Jacobson CF. 2001. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food and Chemical Toxicology 39:209-228.
26. Doherty MM, Charman WN. 2002. The mucosa of the small intestine - how clinically relevant as an organ of drug metabolism? Clinical Pharmacokinetics 41:235-253.
27. Dombrowski SM, Desai SY, Marroni M, Cucullo L, Goodrich K, Bingaman W, Mayberg MR, Bengez L, Janigro D. 2001. Over-expression of multiple drug resistance genes in endothelial cells from patients with refractory epilepsy. Epilepsia 42:1501-1506.
28. Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M. 1992. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80:2729-2734.
29. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB. 2002. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clinical Pharmacology and Therapeutics 71:11-20.
30. Ejsing TB, Linnet K. 2005. Influence of P-glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood-brain barrier. Human Psychopharmacology 20:149-153.
31. El Ela AA, Hartter S, Schmitt U, Hiemke C, Spahn-Langguth H, Langguth P. 2004. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds - implications for pharmacokinetics of selected substrates. Journal of Pharmacy and Pharmacology 56:967-975.
32. Eloranta JJ, Meier PJ, Kullak-Ublick GA. 2005. Coordinate transcriptional regulation of transport and metabolism. Methods in Enzymology 400:511-530.
33. Endres CJ, Hsiao P, Chung FS, Unadkat JD. 2006. The role of transporters in drug interactions. European Journal of Pharmaceutical Sciences 27:501-517.
34. Englund G, Rorsman F, Ronnblom A, Karlbom U, Lazorova L, Grasjo J, Kindmark A, Artursson P. 2006. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. European Journal of Pharmaceutical Sciences 29:269-277.
35. Ezzet F, Wexler D, Statkevich P, Kosoglou T, Patrick J, Lipka L, Mellars L, Veltri E, Batra V. 2001. The plasma concentration and LDL-C relationship in patients receiving ezetimibe. Journal of Clinical Pharmacology 41:943-949.
36. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, et al. 2002. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study. Lancet 359:30-36.
37. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, et al. 2002. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. Journal of Clinical Investigation 110:1309-1318.
38. Fischer V, Einolf HJ, Cohen D. 2005. Efflux transporters and their clinical relevance. Mini Reviews in Medicinal Chemistry 5:183-195.
39. Flens MJ, Zaman GJ, van der Valk P, Izquierdo MA, Schroeijers AB, Scheffer GL, van der Groep P, De Haas M, Meijer CJ, Scheper RJ. 1996. Tissue distribution of the multidrug resistance protein. American Journal of Pathology 148:1237-1247.
40. Frank MH, Denton MD, Alexander SI, Khoury SJ, Sayegh MH, Briscoe DM. 2001. Specific MDR1 P-glycoprotein blockade inhibits human alloimmune T cell activation in vitro. Journal of Immunology 166:2451-2459.
41. Fricker G, Drewe J, Huwyler J, Gutmann H, Beglinger C. 1996. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. British Journal of Pharmacology 118:1841-1847.
42. Fricker G, Miller DS. 2004. Modulation of drug transporters at the blood-brain barrier. Pharmacology 70:169-176.
43. Fromm MF. 2004. Importance of P-glycoprotein at blood-tissue barriers. Trends in Pharmacological Sciences 25:423-429.
44. Fudio S, Carcas A, Pinana E, Ortega R. 2006. Epileptic seizures caused by low valproic acid levels from an interaction with meropenem. Journal of Clinical Pharmacology and Therapeutics 31:393-396.
45. Fux R, Morike K, Gundel UF, Hartmann R, Gleiter CH. 2004. Ezetimibe and statin-associated myopathy. Annals of Internal Medicine 140:671-672.
46. Gallo JM, Li S, Guo P, Reed K, Ma J. 2003. The effect of P-glycoprotein on paclitaxel brain and brain tumor distribution in mice. Cancer Research 63:5114-5117.
47. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis Jr, HR, Dean DC, Detmers PA, et al. 2005. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proceedings of the National Academy of Sciences, USA 102:8132-8137.
48. Glaeser H, Bailey DG, Dresser GK, Gregor JC, Schwarz UI, McGrath JS, Jolicoeur E, Lee W, Leake BF, Tirona RG, et al. 2007. Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clinical Pharmacology and Therapeutics 81:362-370.
49. Graff CL, Pollack GM. 2004. Drug transport at the blood-brain barrier and the choroid plexus. Current Drug Metabolism 5:95-108.
50. Gramatte T, Oertel R, Terhaag B, Kirch W. 1996. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans. Clinical Pharmacology and Therapeutics 59:541-549.
51. Grube M, Kock K, Oswald S, Draber K, Meissner K, Eckel L, Bohm M, Felix SB, Vogelgesang S, Jedlitschky G, et al. 2006a. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clinical Pharmacology and Therapeutics 80:607-620.
52. Grube M, Meyer Zu Schwabedissen HE, Prager D, Haney J, Moritz KU, Meissner K, Rosskopf D, Eckel L, Bohm M, et al. 2006b. Uptake of cardiovascular drugs into the human heart: Expression, regulation, and function of the carnitine transporter OCTN2 (SLC22A5). Circulation 113:1114-1122.
53. Gutmann H, Hruz P, Zimmermann C, Beglinger C, Drewe J. 2005. Distribution of breast cancer resistance protein (BCRP/ABCG2) mRNA expression along the human GI tract. Biochemical Pharmacology 70:695-699.
54. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, De Gruttda, et al. 2005. Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. Journal of Infectious Diseases 192:1931-1942.
55. Hagenbuch B, Meier PJ. 2004. Organic anion transporting polypeptides of the OATP/SLC21 family: Phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Archive: European Journal of Physiology 447:653-665.
56. Hasannejad H, Takeda M, Narikawa S, Huang XL, Enomoto A, Taki K, Niwa T, Jung SH, Onozato ML, Tojo A, et al. 2004. Human organic cation transporter 3 mediates the transport of antiarrhythmic drugs. European Journal of Pharmacology 499:45-51.
57. Ho RH, Kim RB. 2005. Transporters and drug therapy: implications for drug disposition and disease. Clinical Pharmacology and Therapeutics 78:260-277.
58. Huff MW, Pollex RL, Hegele RA. 2006. NPC1L1: evolution from pharmacological target to physiological sterol transporter. Arteriosclerosis, Thrombosis and Vascular Biology 26:2433-2438.
59. Igel M, Arnold KA, Niemi M, Hofmann U, Schwab M, Lutjohann D, Von Bergmann K, Eichelbaum M, Kivisto KT. 2006. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin. Clinical Pharmacology and Therapeutics 79:419-426.
60. Ito K, Suzuki H, Horie T, Sugiyama Y. 2005. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharmaceutical Research 22:1559-1577.
61. Janneh O, Owen A, Chandler B, Hartkoorn RC, Hart CA, Bray PG, Ward SA, Back DJ, Khoo SH. 2005. Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS 19:2097-2102.
62. Jedlitschky G, Burchell B, Keppler D. 2000. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. Journal of Biological Chemistry 275:30069-30074.
63. Jeong EJ, Liu X, Jia X, Chen J, Hu M. 2005. Coupling of conjugating enzymes and efflux transporters: Impact on bioavailability and drug interactions. Current Drug Metabolism 6:455-468.
64. Jones K, Bray PG, Khoo SH, Davey RA, Meaden ER, Ward SA, Back DJ. 2001a. P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS 15:1353-1358.
65. Jones K, Hoggard PG, Sales SD, Khoo S, Davey R, Back DJ. 2001b. Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 15:675-681.
66. Jonker JW, Buitelaar M, Wagenaar E, Van der Valk MA, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, et al. 2002. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proceedings of the National Academy of Sciences, USA 99:15649-15654.
67. Jorajuria S, Dereuddre-Bosquet N, Naissant-Storck K, Dormont D, Clayette P. 2004. Differential expression levels of MRP1, MRP4, and MRP5 in response to human immunodeficiency virus infection in human macrophages. Antimicrobial Agents and Chemotherapy 48:1889-1891.
68. Kajosaari LI, Niemi M, Neuvonen M, Laitila J, Neuvonen PJ, Backman JT. 2005. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clinical Pharmacology and Therapeutics 78:388-399.
69. Katsura T, Inui K. 2003. Intestinal absorption of drugs mediated by drug transporters: Mechanisms and regulation. Drug Metabolism and Pharmacokinetics 18:1-15.
70. Katz DA, Carr R, Grimm DR, Xiong H, Holley-Shanks R, Mueller T, Leake B, Wang Q, Han L, Wang PG, et al. 2006. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clinical Pharmacology and Therapeutics 79:186-196.
71. Kawahara M, Sakata A, Miyashita T, Tamai I, Tsuji A. 1999. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. Journal of Pharmaceutical Sciences 88:1281-1287.
72. Kemper EM, Boogerd W, Thuis I, Beijnen JH, Van Tellingen O. 2004. Modulation of the blood-brain barrier in oncology: Therapeutic opportunities for the treatment of brain tumours? Cancer Treatment Reviews 30:415-423.
73. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR. 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. Journal of Clinical Investigation 101:289-294.
74. Kivisto KT, Niemi M. 2007. Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharmaceutical Research 24:239-247.
75. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. 2003. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. Journal of Pharmacology and Experimental Therapeutics 306:703-708.
76. Kock K, Grube M, Jedlitschky G, Oevermann L, Siegmund W, Ritter CA, Kroemer HK. 2007. Expression of adenosine triphosphate-binding cassette (ABC) drug transporters in peripheral blood cells: Relevance for physiology and pharmacotherapy. Clinical Pharmacokinetics 46:449-470.
77. Konig J, Seithel A, Gradhand U, Fromm MF. 2006. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Archives in Pharmacology 372:432-443.
78. Kopplow K, Letschert K, Konig J, Walter B, Keppler D. 2005. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. Molecular Pharmacology 68:1031-1038.
79. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. 2005. Ezetimibe: A review of its metabolism, pharmacokinetics and drug interactions. Clinical Pharmacokinetics 44:467-494.
80. Krause MS, Oliveira Jr, LP, Silveira EM, Vianna DR, Rossato JS, Almeida BS, Rodrigues MF, Fernandes AJ, Costa JA, Curi R, et al. 2007. MRP1/GS-X pump ATPase expression: is this the explanation for the cytoprotection of the heart against oxidative stress-induced redox imbalance in comparison with skeletal muscle cells? Cell Biochemistry and Function 25:23-32.
81. Kullak-Ublick GA, Ismair MG, Stieger B, Landmann L, Huber R, Pizzagalli F, Fattinger K, Meier PJ, Hagenbuch B. 2001. Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120:525-533.
82. Kullak-Ublick GA, Stieger B, Meier PJ. 2004. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 126:322-342.
83. Kunta JR, Sinko PJ. 2004. Intestinal drug transporters: in vivo function and clinical importance. Current Drug Metabolism 5:109-124.
84. Kusuhara H, Sugiyama Y. 2005. Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx 2:73-85.
85. Kuypers DR. 2005. Benefit-risk assessment of sirolimus in renal transplantation. Drug Safety 28:153-181.
86. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. 2004. Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. British Journal of Clinical Pharmacology 57:181-187.
87. Lau YY, Huang Y, Frassetto L, Benet LZ. 2007. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clinical Pharmacology and Therapeutics 81:194-204.
88. Lee W, Kim RB. 2004. Transporters and renal drug elimination. Annual Reviews in Pharmacology and Toxicology 44:137-166.
89. Leier I, Jedlitschky G, Buchholz U, Center M, Cole SP, Deeley RG, Keppler D. 1996. ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. Biochemistry Journal 314(2):433-437.
90. Lennernas H. 2003. Intestinal drug absorption and bioavailability: Beyond involvement of single transport function. Journal of Pharmacy and Pharmacology 55:429-433.
91. Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ. 2003. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clinical Pharmacology and Therapeutics 73:192-198.
92. Lilja JJ, Raaska K, Neuvonen PJ. 2005. Effects of grapefruit juice on the pharmacokinetics of acebutolol. British Journal of Clinical Pharmacology 60:659-663.
93. Loscher W, Potschka H. 2005a. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2:86-98.
94. Loscher W, Potschka H. 2005b. Drug resistance in brain diseases and the role of drug efflux transporters. Nature Reviews in Neuroscience 6:591-602.
95. Ludescher C, Pall G, Irschick EU, Gastl G. 1998. Differential activity of P-glycoprotein in normal blood lymphocyte subsets. British Journal of Haematology 101:722-727.
96. Maeda K, Ieiri I, Yasuda K, Fujino A, Fujiwara H, Otsubo K, Hirano M, Watanabe T, Kitamura Y, Kusuhara H, et al. 2006. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clinical Pharmacology and Therapeutics 79:427-439.
97. Mahalati K, Kahan BD. 2001. Clinical pharmacokinetics of sirolimus. Clinical Pharmacokinetics 40:573-585.
98. Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y. 2005. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. Journal of Pharmacology and Experimental Therapeutics 314:1059-1067.
99. Meaden ER, Hoggard PG, Newton P, Tjia JF, Aldam D, Cornforth D, Lloyd J, Williams I, Back DJ, Khoo SH. 2002. P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals. Journal of Antimicrobial Chemotherapy 50:583-588.
100. Meier Y, Eloranta JJ, Darimont J, Ismair MG, Hiller C, Fried M, Kullak-Ublick GA, Vavricka SR. 2007. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metabolism and Disposition 35:590-594.
101. Meissner K, Heydrich B, Jedlitschky G, Meyer zu SH, Mosyagin I, Dazert P, Eckel L, Vogelgesang S, Warzok RW, Bohm M, et al. 2006. The ATP-binding cassette transporter ABCG2 (BCRP), a marker for side population stem cells, is expressed in human heart. Journal of Histochemistry and Cytochemistry 54:215-221.
102. Meissner K, Jedlitschky G, Meyer zu SH, Dazert P, Eckel L, Vogelgesang S, Warzok RW, Bohm M, Lehmann C, Wendt M, et al. 2004. Modulation of multidrug resistance P-glycoprotein 1 (ABCB1) expression in human heart by hereditary polymorphisms. Pharmacogenetics 14:381-385.
103. Meissner K, Kessler W, Meyer zu Schwabedissen H, Schuster K, Saalfeld K, Grube M, Buck A, Jedlitschky G, Maier S, et al. (2007). Sepsis affects cardiac expression of multidrug resistance protein 5 (MRP5, ABCC5), an ABC-type cGMP export pump. Shock (accepted).
104. Meissner K, Sperker B, Karsten C, Zu Schwabedissen HM, Seeland U, Bohm M, Bien S, Dazert P, Kunert-Keil C, Vogelgesang S, et al. 2002. Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy. Journal of Histochemistry and Cytochemistry 50:1351-1356.
105. Morimoto K, Oishi T, Ueda S, Ueda M, Hosokawa M, Chiba K. 2004. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metabolism and Pharmacokinetics 19:453-455.
106. Morimoto K, Ueda S, Seki N, Igawa Y, Kameyama Y. 2005. OATP-C (OATP1B1)*15 is associated with statin-induced myopathy in hypercholesterolemic patients. Clinical Pharmacology and Therapeutics 77:P21.
107. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T. 2004. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clinical Pharmacology and Therapeutics 75:415-421.
108. Nacarkucuk E, Saglam H, Okan M. 2004. Meropenem decreases serum level of valproic acid. Pediatric Neurology 31:232-234.
109. Neuvonen PJ, Niemi M, Backman JT. 2006. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clinical Pharmacology and Therapeutics 80:565-581.
110. Nezu J, Tamai I, Oku A, Ohashi R, Yabuuchi H, Hashimoto N, Nikaido H, Sai Y, Koizumi A, Shoji Y, et al. 1999. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nature Genetics 21:91-94.
111. Niemi M, Backman JT, Kajosaari LI, Leathart JB, Neuvonen M, Daly AK, Eichelbaum M, Kivisto KT, Neuvonen PJ. 2005a. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clinical Pharmacology and Therapeutics 77:468-478.
112. Niemi M, Kivisto KT, Hofmann U, Schwab M, Eichelbaum M, Fromm MF. 2005b. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). British Journal of Clinical Pharmacology 59:602-604.
113. Niemi M, Neuvonen PJ, Hofmann U, Backman JT, Schwab M, Lutjohann D, Von Bergmann K, Eichelbaum M, Kivisto KT. 2005c. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17. Pharmacogenetics and Genomics 15:303-309.
114. Niemi M, Schaeffeler E, Lang T, Fromm MF, Neuvonen M, Kyrklund C, Backman JT, Kerb R, Schwab M, Neuvonen PJ, et al. 2004. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14:429-440.
115. Nishimura M, Naito S. 2005. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metabolism and Pharmacokinetics 20:452-477.
116. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. 2004. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. Journal of Pharmacology and Experimental Therapeutics 308:438-445.
117. Nutting DF, Kumar NS, Siddiqi SA, Mansbach CM. 2002. Nutrient absorption. Current Opinion in Gastroenterology 18:168-175.
118. Oerlemans R, Van der HJ, Vink J, Dijkmans BA, Kaspers GJ, Lems WF, Scheffer GL, Ifergan I, Scheper RJ, Cloos J, et al. 2006. Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance-associated protein 1 and provokes high levels of cross-resistance to glucocorticoids. Arthritis and Rheumatism 54:557-568.
119. Ogawa K, Yumoto R, Hamada N, Nagai J, Takano M. 2006. Interaction of valproic acid and carbapenem antibiotics with multidrug resistance-associated proteins in rat erythrocyte membranes. Epilepsy Research 71:76-87.
120. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A. 1999. Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. Journal of Pharmacology and Experimental Therapeutics 291:778-784.
121. Omoda K, Murakami T, Yumoto R, Nagai J, Maeda Y, Kiribayashi Y, Takano M. 2005. Increased erythrocyte distribution of valproic acid in pharmacokinetic interaction with carbapenem antibiotics in rat and human. Journal of Pharmaceutical Sciences 94:1685-1693.
122. Oselin K, Mrozikiewicz PM, Pahkla R, Roots I. 2003. Quantitative determination of the human MRP1 and MRP2 mRNA expression in FACS-sorted peripheral blood CD4+, CD8+, CD19+, and CD56+ cells. European Journal of Haematology 71:119-123.
123. Oswald S, Giessmann T, Luetjohann D, Wegner D, Rosskopf D, Weitschies W, Siegmund W. 2006a. Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins. Clinical Pharmacology and Therapeutics 80:477-485.
124. Oswald S, Haenisch S, Fricke C, Sudhop T, Remmler C, Giessmann T, Jedlitschky G, Adam U, Dazert E, Warzok R. 2006b. Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clinical Pharmacology and Therapeutics 79:206-217.
125. Oswald S, Koll C, Siegmund W. 2007. Disposition of the cholesterol absorption inhibitor ezetimibe in mdr1a/b (-/-) mice. Journal of Pharmaceutical Sciences (accepted).
126. Oswald S, Westrup S, Grube M, Kroemer HK, Weitschies W, Siegmund W. 2006c. Disposition and sterol-lowering effect of ezetimibe in multidrug resistance-associated protein 2-deficient rats. Journal of Pharmacology and Experimental Therapeutics 318:1293-1299.
127. Owen A, Khoo SH. 2004. Intracellular pharmacokinetics of antiretroviral agents. Journal of HIV Therapy 9:97-101.
128. Pauli-Magnus C, Meier PJ. 2005. Hepatocellular transporters and cholestasis. Journal of Clinical Gastroenterology 39:S103-S110.
129. Petri N, Borga O, Nyberg L, Hedeland M, Bondesson U, Lennernas H. 2006. Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers. International Journal of Clinical Pharmacology and Therapeutics 44:71-79.
130. Potschka H, Fedrowitz M, Loscher W. 2001. P-glycoprotein and multidrug resistance-associated protein are involved in the regulation of extracellular levels of the major antiepileptic drug carbamazepine in the brain. Neuroreport 12:3557-3560.
131. Potschka H, Fedrowitz M, Loscher W. 2002. P-glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: Evidence from microdialysis experiments in rats. Neuroscience Letters 327:173-176.
132. Potschka H, Loscher W. 2001. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood-brain barrier of rats. Epilepsia 42:1231-1240.
133. Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J, Balzarini J, Borst P. 2003. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Molecular Pharmacology 63:1094-1103.
134. Riffkin CD, Chung R, Wall DM, Zalcberg JR, Cowman AF, Foley M, Tilley L. 1996. Modulation of the function of human MDR1 P-glycoprotein by the antimalarial drug mefloquine. Biochemical Pharmacology 52:1545-1552.
135. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M. 2002a. Enterohepatic circulation: Physiological, pharmacokinetic and clinical implications. Clinical Pharmacokinetics 41:751-790.
136. Roberts RL, Joyce PR, Mulder RT, Begg EJ, Kennedy MA. 2002b. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics Journal 2:191-196.
137. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. 2000. Increased drug delivery to the brain by P-glycoprotein inhibition. Clinical Pharmacology and Therapeutics 68:231-237.
138. Satoh H, Yamashita F, Tsujimoto M, Murakami H, Koyabu N, Ohtani H, Sawada Y. 2005. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metabolism and Disposition 33:518-523.
139. Schinkel AH, Wagenaar E, Molecular CA, Van Deemter L. 1996. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. Journal of Clinical Investigation 97:2517-2524.
140. Schinkel AH, Wagenaar E, Van Deemter L, Molecular CA, Borst P. 1995. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. Journal of Clinical Investigation 96:1698-1705.
141. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS, Raza A. 2004. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clinical Pharmacology and Therapeutics 75:455-463.
142. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, Fridland A. 1999. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Medicine 5:1048-1051.
143. Schwarz UI, Seemann D, Oertel R, Miehlke S, Kuhlisch E, Fromm MF, Kim RB, Bailey DG, Kirch W. 2005. Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clinical Pharmacology and Therapeutics 77:291-301.
144. Sekine T, Miyazaki H, Endou H. 2006. Molecular physiology of renal organic anion transporters. American Journal of Physiology. Renal Physiology 290:F251-F261.
145. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver
146. Shitara Y, Hirano M, Sato H, Sugiyama Y. 2004. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. Journal of Pharmacology and Experimental Therapeutics 311:228-236.
147. Shitara Y, Horie T, Sugiyama Y. 2006. Transporters as a determinant of drug clearance and tissue distribution. European Journal of Pharmaceutical Sciences 27:425-446.
148. Shitara Y, Sugiyama Y. 2006. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: Drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacology and Therapeutics 112:71-105.
149. Simard C, Poirier P. 2006. Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Canadian Journal of Cardiology 22:141-144.
150. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW. 2004. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clinical Pharmacology and Therapeutics 76:167-177.
151. Sisodiya SM, Heffernan J, Squier MV. 1999. Over-expression of P-glycoprotein in malformations of cortical development. Neuroreport 10:3437-3441.
152. Solbach TF, Konig J, Fromm MF, Zolk O. 2006. ATP-binding cassette transporters in the heart. Trends in Cardiovascular Medicine 16:7-15.
153. Srinivas RV, Middlemas D, Flynn P, Fridland A. 1998. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrobial Agents and Chemotherapy 42:3157-3162.
154. Steffansen B, Nielsen CU, Brodin B, Eriksson AH, Andersen R, Frokjaer S. 2004. Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption. European Journal of Pharmaceutical Sciences 21:3-16.
155. Stieger B, Meier Y, Meier PJ. 2007. The bile salt export pump. Pflugers Archive: European Journal of Physiology 453:611-620.
156. Sugawara I, Akiyama S, Scheper RJ, Itoyama S. 1997. Lung resistance protein (LRP) expression in human normal tissues in comparison with that of MDR1 and MRP. Cancer Letters 112:23-31.
157. Summers MA, Moore JL, McAuley JW. 2004. Use of verapamil as a potential P-glycoprotein inhibitor in a patient with refractory epilepsy. Annals of Pharmacotherapy 38:1631-1634.
158. Tachibana-Iimori R, Tabara Y, Kusuhara H, Kohara K, Kawamoto R, Nakura J, Tokunaga K, Kondo I, Sugiyama Y, Miki T. 2004. Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metabolism and Pharmacokinetics 19:375-380.
159. Takane H, Miyata M, Burioka N, Shigemasa C, Shimizu E, Otsubo K, Ieiri I. 2006. Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy. Journal of Human Genetics 51:822-826.
160. Takano M, Yumoto R, Murakami T. 2006. Expression and function of efflux drug transporters in the intestine. Pharmacology and Therapeutics 109:137-161.
161. Terada T, Inui K. 2004. Peptide transporters: Structure, function, regulation and application for drug delivery. Current Drug Metabolism 5:85-94.
162. Thuerauf N, Fromm MF. 2006. The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases. European Archives in Psychiatry and Clinical Neurosciene 256:281-286.
163. Torii M, Takiguchi Y, Izumi M, Fukushima T, Yokota M. 2002. Carbapenem antibiotics inhibit valproic acid transport in Caco-2 cell monolayers. International Journal of Pharmaceutics 233:253-256.
164. Torii M, Takiguchi Y, Saito F, Izumi M, Yokota M. 2001. Inhibition by carbapenem antibiotic imipenem of intestinal absorption of valproic acid in rats. Journal of Pharmacy and Pharmacology 53:823-829.
165. Trauner M, Boyer JL. 2003. Bile salt transporters: Molecular characterization, function, and regulation. Physiology Review 83:633-671.
166. Tukey RH, Strassburg CP. 2001. Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Molecular Pharmacology 59:405-414.
167. Uhr M, Grauer MT. 2003. abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. Journal of Psychiatric Research 37:179-185.
168. Uhr M, Grauer MT, Holsboer F. 2003. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biology and Psychiatry 54:840-846.
169. Uhr M, Steckler T, Yassouridis A, Holsboer F. 2000. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 22:380-387.
170. Van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P, Van Tellingen O. 1996a. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient mice. Journal of the National Cancer Institute 88:994-999.
171. Van Asperen J, Van Tellingen O, Schinkel AH, Beijnen JH. 1999b. Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein. Journal of Pharmacology and Experimental Therapeutics 289:329-333.
172. Van Asperen J, Van Tellingen O, Tijssen F, Schinkel AH, Beijnen JH. 1999b. Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein. British Journal of Cancer 79:108-113.
173. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G, Starzl T. 1995. Clinical pharmacokinetics of tacrolimus. Clinical Pharmacokinetics 29:404-430.
174. Vezmar M, Georges E. 1998. Direct binding of chloroquine to the multidrug resistance protein (MRP): Possible role for MRP in chloroquine drug transport and resistance in tumor cells. Biochemical Pharmacology 56:733-742.
175. Von Richter O, Burk O, Fromm MF, Thon KP, Eichelbaum M, Kivisto KT. 2004. Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: A comparative analysis in paired tissue specimens. Clinical Pharmacology and Therapeutics 75:172-183.
176. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. 2004a. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. International Journal of Neuropsychopharmacology 7:415-419.
177. Wang JS, Taylor R, Ruan Y, Donovan JL, Markowitz JS, Lindsay DV. 2004b. Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacology 29:551-557.
178. Wang JS, Zhu HJ, Markowitz JS, Donovan JL, DeVane CL. 2006. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berlin) 187:415-423.
179. Wang X, Baba M. 2005. The role of breast cancer resistance protein (BCRP/ABCG2) in cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Antiviral Chemistry and Chemotherapy 16:213-216.
180. Weitschies W, Bernsdorf A, Giessmann T, Zschiesche M, Modess C, Hartmann V, Mrazek C, Wegner D, Nagel S, Siegmund W. 2005. The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. Pharmaceutical Research 22:728-735.
181. Woodrow CJ, Krishna S. 2006. Antimalarial drugs: recent advances in molecular determinants of resistance and their clinical significance. Cellular and Molecular Life Science 63:1586-1596.
182. Wu CP, Klokouzas A, Hladky SB, Ambudkar SV, Barrand MA. 2005a. Interactions of mefloquine with ABC proteins, MRP1 (ABCC1) and MRP4 (ABCC4) that are present in human red cell membranes. Biochemistry and Pharmacology 70:500-510.
183. Wu CP, Woodcock H, Hladky SB, Barrand MA. 2005b. cGMP (guanosine 3′,5′-cyclic monophosphate) transport across human erythrocyte membranes. Biochemical Pharmacology 69:1257-1262.
184. Wu CY, Benet LZ. 2005. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharmaceutical Research 22:11-23.
185. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V. 1998. Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. Journal of Biological Chemistry 273:32776-32786.
186. Xu C, Li CY, Kong AN. 2005. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Archives of Pharmacal Research 28:249-268.
187. Yamagata T, Momoi MY, Murai K, Ikematsu K, Suwa K, Sakamoto K, Fujimura A. 1998. Panipenem-betamipron and decreases in serum valproic acid concentration. Therapeutic and Drug Monitoring 20:396-400.
188. Yasui-Furukori N, Saito M, Nakagami T, Kaneda A, Tateishi T, Kaneko S. 2006. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: A preliminary study. Progress in Neuropsychopharmacology and Biological Psychiatry 30:286-291.
189. Yu L, Bharadwaj S, Brown JM, Ma Y, Du W, Davis MA, Michaely P, Liu P, Willingham MC, Rudel LL. 2006. Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake. Journal of Biological Chemistry 281:6616-6624.
190. Zamek-Gliszczynski MJ, Hoffmaster KA, Nezasa K, Tallman MN, Brouwer KL. 2006. Integration of hepatic drug transporters and phase II metabolizing enzymes: mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. European Journal of Pharmaceutical Sciences 27:447-486.
191. Zhang J, Alston MA, Huang H, Rabin RL. 2006a. Human T cell cytokine responses are dependent on multidrug resistance protein-1. International Immunology 18:485-493.
192. Zhang W, He YJ, Han CT, Liu ZQ, Li Q, Fan L, Tan ZR, Zhang WX, Yu BN, Wang D, et al. 2006b. Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. British Journal of Clinical Pharmacology 62:567-572.
193. Zhang Y, Berger SA. 2003. Ketotifen reverses MDR1-mediated multidrug resistance in human breast cancer cells in vitro and alleviates cardiotoxicity induced by doxorubicin in vivo. Cancer Chemotherapy and Pharmacology 51:407-414.
194. Zhang YC, Benet LZ. 2001. The gut as a barrier to drug absorption - combined role of cytochrome P450 3A and P-glycoprotein. Clinical Pharmacokinetics 40:159-168.
195. Zhou S, Zong Y, Ney PA, Nair G, Stewart CF, Sorrentino BP. 2005. Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels. Blood 105:2571-2576.
196. Zimmermann C, Gutmann H, Hruz P, Gutzwiller JP, Beglinger C, Drewe J. 2005. Mapping of multidrug resistance gene 1 and multidrug resistance-associated protein isoform 1 to 5 mRNA expression along the human intestinal tract. Drug Metabolism and Disposition 33:219-224.
197. Zwart R, Verhaagh S, Buitelaar M, Popp-Snijders C, Barlow DP. 2001. Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice. Molecular and Cellular Biology 21:4188-4196.